Buchumschlag

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma

Background: Advanced pancreatic adenocarcinoma still remains associated with a desperate prognosis. Nevertheless, treatment options for patients with metastasized disease have improved considerably over the last few years. Recently, cytotoxic combination therapies such as the FOLFIRINOX regimen and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Berger, Anne Katrin (VerfasserIn) , Weber, Tim (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Springfeld, Christoph (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: November 20, 2013
In: Onkologie
Year: 2013, Jahrgang: 36, Heft: 12, Pages: 763-765
ISSN:1423-0240
DOI:10.1159/000356811
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000356811
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/356811
Volltext
Verfasserangaben:Anne K. Berger, Tim F. Weber, Dirk Jäger, Christoph Springfeld
Beschreibung
Zusammenfassung:Background: Advanced pancreatic adenocarcinoma still remains associated with a desperate prognosis. Nevertheless, treatment options for patients with metastasized disease have improved considerably over the last few years. Recently, cytotoxic combination therapies such as the FOLFIRINOX regimen and combined nab-paclitaxel/gemcitabine have shown improved overall survival compared to gemcitabine alone. There is still no standard of care in second-line therapy for patients with disease progression. Case Report: We report the case of a 47-year-old patient who dramatically responded to second-line treatment with nab-paclitaxel and gemcitabine after primary progression to the FOLFIRINOX protocol. Conclusion: Second-line treatment after FOLFIRINOX is feasible for patients with good performance status. Our case report supports preclinical findings that suggest that pancreatic cancer is a heterogeneous disease. Further studies that characterize possible subgroups and identify predictive molecular markers to guide therapy are warranted.
Beschreibung:Gesehen am 23.11.2020
Beschreibung:Online Resource
ISSN:1423-0240
DOI:10.1159/000356811

Ähnliche Einträge